eSonics | Inhalation Drug Delivery Device Manufacturing Company Of The
Pharma Tech Outlook

Pharma Tech Outlook

eSonics
Engineering Inhalation Devices Around Drug Performance

eSonics: Engineering Inhalation Devices Around Drug Performance

Leo Shi (LEI), eSonics | Pharma Tech Outlook | Inhalation Drug Delivery Device Manufacturing Company Of The Year In AsiaLeo Shi (LEI), Founder, Chairman of the Managing Board and CEO
eSonics approaches inhalation-device development from the premise that drug performance and device performance cannot be separated. Small variations in component tolerances can affect dose consistency, aerodynamic particle distribution and clinical outcomes, while regulations add requirements around design control, traceability and GMP-aligned manufacturing. Devices must also serve patients with different dexterity and respiratory conditions.

“We believe that successful inhalation-product innovation depends not only on novel drugs, but also on tightly-coupled drug-device co-development,” says Leo Shi (LEI), Founder, Chairman of the Managing Board and CEO of the group.

That thinking shapes eSonics’ work across aerosol, dry-powder, soft-mist and nasal delivery platforms. Rather than applying one engineering model to every device, it adapts its technical focus to the physics of each modality while maintaining common standards for material qualification, risk assessment and design-history documentation.

For pharmaceutical partners without dedicated precision-engineering resources, this model reduces the risk of upfront tooling and prototyping through GMP-aligned prototyping and manufacturing support.

From Requirements to Device Architecture

For pressurized metered-dose aerosol devices, eSonics focuses on valve-canister precision, propellant compatibility, sealing and spray consistency. Dry-powder inhalers require attention to powder flow, dose metering and airflow-driven deagglomeration. Soft-mist devices shift the challenge toward micro-nozzle fluid dynamics, droplet generation and actuation precision, while nasal systems require control of plume geometry, droplet distribution, ergonomics and back-flow risk.

eSonics’ projects follow a structured, phase-gated workflow aligned with pharmaceutical quality by design. Clinical goals, target patients, formulation properties and regulatory targets are translated into user requirements and engineering specifications. Feasibility work then addresses architecture, material screening and technical risks before detailed design, simulation, prototyping and bench-level verification.

Function remains the priority in customization, including dose output, particle or droplet characteristics and mechanical reliability. Human-factor work covers grip, actuation force and visual feedback. Product identification can include laser marking, molded identifiers and serialization-compatible structures, with marking content, readability and durability checked against regulatory needs.
  • We believe that successful inhalation-product innovation depends not only on novel drugs, but also on tightly-coupled drug-device co-development.


Once the design is frozen, eSonics moves into tooling, process development and validation. Production-representative tooling is built, manufacturing processes are established and verification records are prepared. Throughout the process, test data is shared with clients, and development paths can be adjusted if formulation or clinical requirements change.

Compliance Built Into Development

Compliance is treated as part of development rather than a final review. eSonics applies risk-based thinking consistent with ISO 13485, relevant inhalation-device standards and global regulatory expectations. It prepares design-control documentation, while material qualification addresses biocompatibility and chemical compatibility with formulations and propellants.

Testing covers mechanical safety, material stability and contamination risk. When standards change, eSonics performs gap assessments for ongoing projects and updates documentation that clients can use in regulatory submissions.

A recent nasal-delivery project shows the process in practice. A biotech client needed a custom device capable of precise droplet-size distribution for upper-nasal-cavity deposition, which available off-theshelf devices could not achieve. eSonics used fluid-dynamic simulation and successive prototypes for spray-pattern and dose-uniformity testing, alongside compatibility studies with the client’s proprietary liquid formulation.

The team refined mechanical structures to address back-flow risk and improve patient ergonomics. The resulting prototype hardware met the client’s performance thresholds and was delivered with design-verification records to support preclinical and early clinical programs.

A Long-Term Technical Extension

Pharmaceutical customers value eSonics for understanding drug-device combination risks, not only mechanical part design. Its support continues through responsive technical reviews, objective test data feedback, manufacturing process transfer, component supply continuity, engineering change management and regulatory document updates. This continuity reflects its role as a long-term technical extension of the client’s team.

As an Asia-based specialized inhalation-device CDMO, eSonics continues to invest in precision metal-plastic capability, multi-modality prototyping and regulatory-competent talent. It aims to lower development barriers for Asian biotech innovators and global pharma partners as inhaled therapeutics expand into nasal-delivered systemic therapies, mucosal immunology and local-targeted treatments.

Its ability to connect device engineering, compliance, manufacturing and long-term technical support has earned it recognition as Inhalation Drug Delivery Device Manufacturing Company of the Year in Asia 2026.

Deep Dive

When Inhalation Device Manufacturing Becomes a Drug Development Constraint

Inhalation device programs can lose months when a formulation reaches engineering before the delivery hardware has been tested against it. A small tolerance shift can change dose output or aerosol behavior, while an unsuitable material can create compatibility problems late in development. An inhalation device partner must deliver more than manufacturing precision. It must be able to connect pharmaceutical requirements to repeatable device performance without allowing tooling decisions or design changes to become a new source of development risk. Commercial pressure complicates this further. Early programs need enough prototype fidelity to expose dose and usability risks, but committing too early to production tooling can lock in a device architecture before formulation and clinical requirements have settled. That makes the staging of engineering spend part of the technical evaluation.  That starts with the depth of drug-device engineering. Metered-dose inhalers, dry powder devices, soft-mist systems and nasal delivery products do not fail for the same reasons. Valve and canister precision can dominate one program, while another depends on powder flow or airflow-driven de-agglomeration. Soft-mist designs place more weight on nozzle behavior and actuation control, while nasal products bring spray geometry and contamination control into sharper focus. A manufacturer should be able to adapt its engineering approach to the delivery mechanism rather than force different products through the same design logic. Early compatibility work matters because formulation properties and component design influence each other long before production tooling is fixed.  Regulatory readiness is equally hard to separate from engineering quality. Design inputs, risk records, verification evidence and traceable revisions need to be developed alongside the hardware rather than appear at the end as a documentation exercise. Material qualification also has to address both patient safety and formulation compatibility. That becomes especially important when a project moves across development stages or when standards change during the program. Buyers should examine whether the manufacturing partner can maintain design-history discipline while keeping test results, engineering changes, process records and validation records usable for later regulatory submissions.  “eSonics Group also builds regulatory documentation, material qualification, validation evidence and risk records into development rather than adding them after design completion.” The handoff from concept work to repeatable production is another point where attractive prototypes can become expensive programs. Custom device development often involves iterative mechanical design and simulation before production-representative tooling is justified. The manufacturer should be able to absorb that progression without losing control of functional requirements. Human factors also belong in this discussion. Grip, actuation force, visual feedback and product identification can affect usability, but none should compromise dose delivery or manufacturability. A disciplined partner treats these as design constraints that must be tested against the same performance baseline as the core delivery mechanism.  eSonics Group develops inhalation devices through a phase-gated process that links requirement definition, feasibility work, detailed design and manufacturing validation. It works across aerosol, dry powder, soft mist and nasal platforms, changing the engineering focus to match the physics of each delivery method. eSonics Group also builds regulatory documentation, material qualification, validation evidence and risk records into development rather than adding them after design completion. Its combination of precision metal-plastic component engineering, GMP-aligned prototyping, manufacturing process development and production-transfer support addresses the points where pharmaceutical programs commonly lose time or traceability. For teams that need customized inhalation hardware backed by disciplined development documentation, eSonics Group merits consideration as a manufacturing partner.  ...Read more

Inhalation Drug Delivery Device Manufacturing Companies in Asia Info

Q1

What Are Inhalation Drug Delivery Device Manufacturing Companies, And What Do They Cover?

Inhalation Drug Delivery Device Manufacturing Companies develop and produce devices that deliver medicines through the respiratory or nasal route. Their work can cover device architecture, engineering, prototyping, tooling, process development, validation and manufacturing. Depending on the delivery method, development may address dose metering, airflow, spray behavior, sealing, fluid dynamics, material compatibility and patient handling. The scope can extend from early feasibility work through production support, making control over design records, testing and manufacturing important throughout development.

Q2

How Does eSonics Approach Inhalation Drug Delivery Device Manufacturing Companies?

eSonics treats the drug and device as connected parts of the product development process. Its work spans aerosol, dry-powder, soft-mist and nasal platforms, with engineering priorities adapted to the physics of each modality. The company also uses phase-gated development to translate clinical goals, target patients, formulation properties and regulatory requirements into engineering specifications before detailed design, simulation, prototyping and verification. This approach gives development teams a defined path from requirements to production-representative tooling and documented verification.

Q3

What Problems Can Inhalation Device Manufacturing Help Pharmaceutical And Biotech Teams Address?

Inhalation device manufacturing can help teams manage challenges that sit between a formulation and its intended delivery performance. These can include dose consistency, particle or droplet characteristics, device reliability, material compatibility and human factors. A structured development process can also bring design risks and regulatory requirements into the project earlier, reducing the chance that important issues emerge only after the device has progressed into later development stages. It can also support changes when formulation or clinical requirements shift during development.

Q4

Which Technical Factors Matter When Evaluating Inhalation Drug Delivery Device Manufacturing Companies?

The technical factors depend on the delivery platform and the intended use. For pressurized aerosol devices, valve-canister precision, propellant compatibility, sealing and spray consistency may be central. Dry-powder devices require attention to powder flow, dose metering and deagglomeration. Soft-mist systems involve micro-nozzle fluid dynamics and actuation precision, while nasal devices may require control of plume geometry, droplet distribution, ergonomics and back-flow risk. Material qualification, risk assessment, design verification and regulatory documentation are also relevant when judging whether development work can progress toward compliant manufacturing.

Q5

What Makes eSonics Relevant To Inhalation Drug Delivery Device Manufacturing Companies?

eSonics combines precision device engineering with compliance, testing and manufacturing support. Its development work includes material qualification, risk assessment and design-history documentation, while testing addresses mechanical safety, material stability and contamination risk. In one nasal-delivery project, it used fluid-dynamic simulation, successive prototypes, spray-pattern and dose-uniformity testing and formulation compatibility studies to refine a device for precise droplet-size distribution. The resulting prototype met the client's performance thresholds and was delivered with design-verification records for preclinical and early clinical programs.

Q6

How Can Inhalation Drug Delivery Device Manufacturing Companies Support Development Beyond Prototyping?

Inhalation Drug Delivery Device Manufacturing Companies can remain involved after a design reaches production readiness through tooling, process development, validation, manufacturing transfer and component supply support. eSonics also provides technical reviews, engineering change management and regulatory document updates. This broader involvement can help maintain continuity as formulation, clinical or regulatory requirements change during the product lifecycle. That continuity can matter when device performance, documentation and manufacturing requirements need to stay aligned across later development stages.

Inhalation Drug Delivery Device Manufacturing Company Of The Year In Asia 2026

Company
eSonics

Management
Leo Shi (LEI), Founder, Chairman of the Managing Board and CEO

Description
eSonics is an Asia-based specialized inhalation-device CDMO providing design, engineering, prototyping, manufacturing and regulatory support across aerosol, dry-powder, soft-mist and nasal platforms. Its device-centric approach combines formulation compatibility, precision component development, compliance, validation and long-term technical support for pharmaceutical and biotech partners across regional markets.